Drostanolone Enanthate (Masteron) 200 mg

Drostanolone Enanthate (Masteron) 200 mg is Hilma Biocare's long-ester drostanolone injectable, supplied as a 10 ml vial at 200 mg/ml. Drostanolone is a dihydrotestosterone derivative that does not aromatise, and the enanthate ester stretches its release over a far longer window than the propionate version. Each vial is sealed in a printed carton with a scratch-off authenticity code.

What Drostanolone Enanthate Is

Drostanolone is a synthetic anabolic androgenic steroid structurally related to dihydrotestosterone, with a methyl group at carbon two that protects it from metabolic breakdown. Because it is already a reduced androgen, it cannot be converted to oestradiol by aromatase and is not a substrate for 5-alpha reductase in the usual sense. The result is a compound associated with dryness, density and hardening rather than water retention. The enanthate ester makes it practical for longer protocols by slowing release significantly.

The History of Masteron

Drostanolone was developed in the late 1950s and reached the market in the 1960s under names such as Masteril and Drolban, initially for breast-cancer palliation in postmenopausal women. It later appeared in veterinary and physique contexts, where the "Masteron" name became shorthand for a hard, dry look. The propionate ester was the classic presentation; the enanthate version arrived later as researchers sought less frequent administration with the same non-aromatising profile.

How It Works

The enanthate ester is hydrolysed gradually after intramuscular injection, producing a slow release of free drostanolone over roughly one to two weeks. Drostanolone binds the androgen receptor with high affinity and, because it does not aromatise, it does not raise oestradiol or cause oestrogen-driven water retention. It is metabolised in the liver and excreted mainly in urine. The long ester smooths the curve and reduces peak-to-trough variation, which is the main pharmacological reason to choose enanthate over propionate.

What the Research Shows

• Drostanolone was investigated in the 1960s and 1970s as endocrine therapy for advanced breast cancer.
• Its non-aromatising profile has made it a reference compound in studies of androgen receptor binding.
• Comparative pharmacokinetic work shows enanthate esters produce markedly longer release than propionate.
• Contemporary research interest centres on its effects on lean tissue and conditioning rather than mass.

Research Context

Drostanolone's clinical research was concentrated in breast cancer, where it was used as endocrine therapy in postmenopausal women in the 1960s and 1970s. Those studies documented objective responses in a subset of patients, although it was eventually superseded by safer agents. Analytical work has characterised its urinary metabolites, and detection methods are well established. The long enanthate ester extends the detection window compared with propionate, which is a relevant consideration in anti-doping research.

Strength, Pack and Authentication

Each millilitre contains 200 mg of drostanolone enanthate, giving 2000 mg per 10 ml vial. The vial is filled under controlled conditions, sealed with a colour-coded flip-off cap and boxed with a printed carton that states the compound, strength and volume. A scratch-off security code inside the box allows verification against Hilma Biocare's records.

Buying Masteron Enanthate Online

Masteron enanthate is one of the most searched long-ester hardening compounds. If you are researching drostanolone enanthate, comparing masteron 200 products or looking to buy drostanolone online from a trusted Hilma Biocare supplier, this page gives you the complete specification, pack size, price and stock status. Browse more Hilma Biocare injectables at NotNatty.